DDS-1 and UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial

Overview

Journal Nutrients

Date 2020 Feb 6

PMID 32019158

Citations 47

Authors

Christopher J Martoni

Shalini Srivastava

Gregory J Leyer

Affiliations

Soon will be listed here.

Abstract

This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, DDS-1 (1 × 10 CFU/day) or subsp. UABla-12 (1 × 10 CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: -2.59 ± 2.07, p = 0.001; UABla-12: -1.56 ± 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p < 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (-133.4 ± 95.19, p < 0.001) and B. lactis UABla-12 (-104.5 ± 96.08, p < 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.

Citing Articles

Comparison of Rifaximin Monotherapy and Rifaximin Combined with Probiotics in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial.

Oh C, Chung H, Kim Y, Kim J Nutrients. 2025; 17(5).

PMID: 40077633 PMC: 11901931. DOI: 10.3390/nu17050763.

Ginsenoside Reshapes Intestinal Microecology to Alleviate Microgravity Stress.

Wang Y, Chen T, Shi Z, Dong L, Li M, Peng B Drug Des Devel Ther. 2025; 19:1289-1303.

PMID: 40026331 PMC: 11869762. DOI: 10.2147/DDDT.S486371.

Adjunct Therapies to Standard Care for IBS and IBD Patients: Digestive Symptoms Improvement and Quality of Life Optimization.

Traynard V Nutrients. 2024; 16(22).

PMID: 39599713 PMC: 11597149. DOI: 10.3390/nu16223927.

A Review of Pharmacologic and Non-Pharmacologic Therapies in the Management of Irritable Bowel Syndrome: Current Recommendations and Evidence.

Papale A, Flattau R, Vithlani N, Mahajan D, Nadella S J Clin Med. 2024; 13(22).

PMID: 39598092 PMC: 11594791. DOI: 10.3390/jcm13226948.

Probiotic Potential in Irritable Bowel Syndrome and Inflammatory Bowel Disease: A Comprehensive Systematic Review.

Manandhar A, Sabir G, Abdelhady H, Oumar Abakar A, Gangavarapu R, Mahmud S Cureus. 2024; 16(10):e72089.

PMID: 39575029 PMC: 11581459. DOI: 10.7759/cureus.72089.

References

Holtmann G, Ford A, Talley N . Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 1(2):133-146. DOI: 10.1016/S2468-1253(16)30023-1. View

Ranuh R, Athiyyah A, Darma A, Risky V, Riawan W, Surono I . Effect of the probiotic IS-10506 on BDNF and 5HT stimulation: role of intestinal microbiota on the gut-brain axis. Iran J Microbiol. 2019; 11(2):145-150. PMC: 6635314. View

Gerasimov S, Ivantsiv V, Bobryk L, Tsitsura O, Dedyshin L, Guta N . Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial. Eur J Clin Nutr. 2015; 70(4):463-9. DOI: 10.1038/ejcn.2015.171. View

Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A . Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002; 122(7):1778-83. DOI: 10.1053/gast.2002.33579. View

Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L . Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2006; 13(1):35-7. DOI: 10.1038/nm1521. View

Ford A, Moayyedi P . Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010; 32(2):144-58. DOI: 10.1111/j.1365-2036.2010.04328.x. View

Ford A, Moayyedi P, Chey W, Harris L, Lacy B, Saito Y . American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018; 113(Suppl 2):1-18. DOI: 10.1038/s41395-018-0084-x. View

Vemuri R, Shinde T, Shastri M, Perera A, Tristram S, Martoni C . A human origin strain DDS-1 exhibits superior probiotic efficacy in comparison to plant or dairy origin probiotics. Int J Med Sci. 2018; 15(9):840-848. PMC: 6036100. DOI: 10.7150/ijms.25004. View

Barbara G, Feinle-Bisset C, Ghoshal U, Quigley E, Santos J, Vanner S . The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016; . DOI: 10.1053/j.gastro.2016.02.028. View

10.

Ringel-Kulka T, Palsson O, Maier D, Carroll I, Galanko J, Leyer G . Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011; 45(6):518-25. PMC: 4372813. DOI: 10.1097/MCG.0b013e31820ca4d6. View

11.

Spiegel B, Bolus R, Harris L, Lucak S, Naliboff B, Esrailian E . Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther. 2009; 30(11-12):1159-70. PMC: 2793273. DOI: 10.1111/j.1365-2036.2009.04144.x. View

12.

Barbara G, Cremon C, Azpiroz F . Probiotics in irritable bowel syndrome: Where are we?. Neurogastroenterol Motil. 2018; 30(12):e13513. DOI: 10.1111/nmo.13513. View

13.

Ringel-Kulka T, Goldsmith J, Carroll I, Barros S, Palsson O, Jobin C . Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study. Aliment Pharmacol Ther. 2014; 40(2):200-7. PMC: 4613798. DOI: 10.1111/apt.12800. View

14.

Qin H, Cheng C, Tang X, Bian Z . Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014; 20(39):14126-31. PMC: 4202343. DOI: 10.3748/wjg.v20.i39.14126. View

15.

Dale H, Rasmussen S, Asiller O, Lied G . Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients. 2019; 11(9). PMC: 6769995. DOI: 10.3390/nu11092048. View

16.

Ghoshal U, Abraham P, Bhatt C, Choudhuri G, Bhatia S, Shenoy K . Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008; 27(1):22-8. View

17.

Turck D, Castenmiller J, de Henauw S, Hirsch-Ernst K, Kearney J, Knutsen H . Guidance on the scientific requirements for health claims related to muscle function and physical performance: (Revision 1). EFSA J. 2020; 16(10):e05434. PMC: 7009729. DOI: 10.2903/j.efsa.2018.5434. View

18.

Patrick D, Drossman D, Frederick I, DiCesare J, Puder K . Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998; 43(2):400-11. DOI: 10.1023/a:1018831127942. View

19.

Spiegel B, Bolus R, Agarwal N, Sayuk G, Harris L, Lucak S . Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther. 2010; 32(10):1275-91. DOI: 10.1111/j.1365-2036.2010.04464.x. View

20.

Mangel A . Study design issues in irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 19(1):141-2. DOI: 10.1046/j.1365-2036.2003.01816.x. View